Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (867)	12/6/2003 10:47:52 AM
From: Jibacoa	Respond to of 1005

Introgen's Advexin Vaccine Therapy to Begin Phase I/II Testing in Breast Cancer Patients. AUSTIN, Texas, Dec. 5 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN) announced today that its vaccine therapy, INGN 225, will be evaluated at two U.S. cancer centers in a phase I/II study to treat patients with advanced breast cancer. An estimated 267,000 new cases of invasive and in situ breast cancer are expected to occur among women in the United States during 2003, resulting in an estimated 39,800 deaths. The trial will be conducted by Drs. Kenneth H. Cowan and Elizabeth Reed at the University of Nebraska Medical Center in Omaha, Nebraska. The H. Lee Moffitt Cancer Center in Tampa, Florida will prepare the vaccine and participate in immunologic evaluations. Enrollment will begin with patients with invasive breast cancer who will receive chemotherapy, in addition to the INGN 225 vaccine. The INGN 225 vaccine was developed based on work by Dr. Dmitry Gabrilovich, Associate Professor of Oncology at the Moffitt Cancer Center and Dr. David Carbone, professor of oncology at The Vanderbilt-Ingram Cancer Center and is exclusively licensed to Introgen Therapeutics. Dr. Gabrilovich said, "A goal of cancer immunologists is the development of viable cancer vaccines. As we progress into human trials for different types of cancer, we are moving closer to achieving that goal. With the high incidence and mortality rates of breast cancer, we are eager to evaluate INGN 225 therapy in cancer patients with this devastating disease. We are excited because this vaccine approach may be applicable to many different kinds of cancer, not just lung and breast." INGN 225 uses Introgen's Advexin drug to stimulate the patient's dendritic cells, which are then used as a therapeutic vaccine to immunize a patient against their cancer. Previously published pre-clinical data from Dr. Gabrilovich's group demonstrated that 60 percent of animals treated with INGN 225 were protected against tumor development. When dendritic cells were activated, 100 percent protection against tumors was achieved. INGN 225 is already being evaluated in patients with small-cell lung cancer, also in a phase I/II study. Advexin therapy, recently designated as a Fast Track Program for head and neck cancer by the FDA, has been evaluated in numerous clinical studies including phase 3 studies for head and neck cancer, as well as phase 1 and 2 studies for various types of cancer. In these studies, Advexin uses the p53 protector gene ("guardian of the genome") to directly kill cancer cells and to stop tumor growth, without harming normal cells. corporate-ir.net